Orbital Therapeutics
- Biotech or pharma, therapeutic R&D
Orbital Tx is a circRNA company with innovative technology, solid investor backing (ARCH, a16z) and very experienced team (John Maraganore, Ron Philip, Gilles Besin).
We are advancing the frontier of programmable RNA therapeutics for autoimmune, oncology, vaccines and protein therapeutics. Our deep toolbox of RNA and delivery technology features targeted lipid nanoparticles (LNPs) and circular RNA to engineer patient-specific immune responses.
One of our key innovations is in vivo CAR-T therapy for B cell depletion, offering a less invasive, lymphodepletion-free approach for a complete immune reset. In vivo CAR also holds promise in oncology as a simpler and safer option for patients versus ex vivo CAR and offers the potential for a multi-antigen approach. Advancements in our next-generation RNA vaccine technology leverage strategies that significantly enhance expression levels, a critical factor for generating robust and durable immune responses to prevent or treat disease.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}